VP, Oncology Clinical Development – Hematology Strategy

GlaxoSmithKline; Waltham (MA); Hybrid; USD 341,000 - 568,000; Full time

Job summary

GlaxoSmithKline seeks a VP, Oncology Clinical Development Disease Area Head to lead end-to-end clinical development for hematology/oncology assets, guiding strategy and cross-functional execution across global programs.

The role requires senior leadership in early- to late-phase oncology, with a focus on trial design, regulatory readiness, and portfolio positioning, in a hybrid US-based setting (Collegeville, PA or Waltham, MA) and globally.

Qualifications

• Medical degree with board certification or eligibility in oncology.
• At least 10 years clinical development experience leading global programs in hematology and oncology.
• Senior clinical and scientific leadership in early- and late-phase oncology drug development.
• Proven track record designing and delivering late-phase clinical trials and regulatory submissions.
• Experience leading geographically dispersed teams and complex multi-stakeholder programs.

Responsibilities

• Lead end-to-end clinical development for oncology assets from first-in-human through launch readiness.
• Shape and drive the scientific and clinical development strategy for assigned disease areas and assets.
• Lead cross-functional teams and governance forums, ensuring continuity and high-quality decisions.
• Act as senior clinical representative in governance forums and external advisory boards.
• Foster enterprise-wide collaboration and external partnerships to accelerate development.

Skills

Hematology/Oncology

Cross-functional Leadership

Regulatory Affairs

Strategic Planning

Portfolio Oversight

Education

Medical degree

Oncology board certification

Job description

GlaxoSmithKline seeks a VP, Oncology Clinical Development Disease Area Head to lead end-to-end clinical development for hematology/oncology assets, guiding strategy and cross-functional execution across global programs.

The role requires senior leadership in early- to late-phase oncology, with a focus on trial design, regulatory readiness, and portfolio positioning, in a hybrid US-based setting (Collegeville, PA or Waltham, MA) and globally.